Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $11.33 in the prior trading day, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $11.68, up 3.09%. In other words, the price has increased by $3.09 from its previous closing price. On the day, 1.17 million shares were traded. DNA stock price reached its highest trading level at $11.965 during the session, while it also had its lowest trading level at $11.04.
Ratios:
Our goal is to gain a better understanding of DNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.41 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 22 ’25 when Coen Steven P. sold 310 shares for $12.40 per share. The transaction valued at 3,843 led to the insider holds 11,112 shares of the business.
Che Austin bought 2,200 shares of DNA for $31,020 on Aug 06 ’25. On Jul 17 ’25, another insider, Coen Steven P., who serves as the insider of the company, sold 1,084 shares for $9.84 each. As a result, the insider received 10,669 and left with 10,679 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 670733376 and an Enterprise Value of 602503872. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.00 while its Price-to-Book (P/B) ratio in mrq is 1.00. Its current Enterprise Value per Revenue stands at 2.61 whereas that against EBITDA is -2.611.
Stock Price History:
The Beta on a monthly basis for DNA is 1.52, which has changed by 1.0672567 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $16.85, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is -2.73%, while the 200-Day Moving Average is calculated to be 20.42%.
Shares Statistics:
The stock has traded on average 1.64M shares per day over the past 3-months and 1641850 shares per day over the last 10 days, according to various share statistics. A total of 43.82M shares are outstanding, with a floating share count of 40.51M. Insiders hold about 27.92% of the company’s shares, while institutions hold 58.34% stake in the company. Shares short for DNA as of 1755216000 were 7101248 with a Short Ratio of 4.34, compared to 1752537600 on 10340727. Therefore, it implies a Short% of Shares Outstanding of 7101248 and a Short% of Float of 15.479999999999999.
Earnings Estimates
The firm’s stock currently is rated by 3.0 analysts. The consensus estimate for the next quarter is -$1.27, with high estimates of -$1.17 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$5.16 and -$5.33 for the fiscal current year, implying an average EPS of -$5.25. EPS for the following year is -$4.35, with 3.0 analysts recommending between -$3.51 and -$4.85.
Revenue Estimates
4 analysts predict $38.95M in revenue for the current quarter. It ranges from a high estimate of $40M to a low estimate of $37.5M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $89.05MFor the next quarter, 4 analysts are estimating revenue of $40.19M. There is a high estimate of $43.7M for the next quarter, whereas the lowest estimate is $37.08M.
A total of 4 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $181M, while the lowest revenue estimate was $175M, resulting in an average revenue estimate of $177.07M. In the same quarter a year ago, actual revenue was $227.04MBased on 4 analysts’ estimates, the company’s revenue will be $202.57M in the next fiscal year. The high estimate is $210M and the low estimate is $194.9M.
